Phyton Biotech operates the world’s largest Plant Cell Fermentation Technology (PCF®) facility with more than 200,000 litres of fermentation capacity and multiple production lines from kilograms to tonnes of product volumes. With their state-of-the-art facilities, they are uniquely equipped to address the entire development chain, including sourcing/selection of plant material, cell line/fermentation/downstream process development, analytical development, semi-synthesis and scale-up to commercial production.
Their company’s inspiring history began in 1990 with the work of two talented postdoctoral fellows at Cornell University in Ithaca, New York. With the objective of developing manufacturing solutions for complex natural phytochemicals using Plant Cell Fermentation Technology (PCF®), they advanced an idea that many people thought would be impossible to realize: to produce Paclitaxel (one of the world’s most important anti-cancer drugs) from plant cell cultures through plant cell fermentation instead of by harvesting rare and slow-growing pacific yew trees.
Today, Phyton Biotech is the world’s largest producer of high-quality Paclitaxel and Docetaxel via PCF®. They also offer comprehensive development services for biopharmaceuticals and phytochemicals using PCF®, serving the pharmaceutical, cosmetic, agricultural and food ingredient industries. Phyton is a subsidiary of DFB Pharmaceuticals.
Leadership Award for Productivity (2012) – Contract Manufacturing Organization
Research Group of the Year Life Sciences Award (2011) – Select Biosciences
Presidential Green Chemistry Challenge: Greener Synthetic Pathways Award
(2004) – United States Environmental Protection Agency